| Literature DB >> 35518596 |
Lifang Jin1,2, Cuizhu Wang1, Jinping Liu1, Pingya Li1, Jing Li3, Xiaoli Cui3, Yi Wang1.
Abstract
Pseudo-ginsengenin DQ (PDQ) is the product of the oxidative cyclization of protopanaxadiol. PDQ exhibits various bioactivities, including reversal of multidrug resistance in cancer, renal protective effects against acute nephrotoxicity and attenuating myocardial ischemia injury induced by isoproterenol or ligation of coronary arterials, but its effect on arrhythmias has not been clear until now. Because of the complicated effects of ginseng on the cardiovascular system, it is necessary to investigate whether PDQ affects arrhythmias, which are always concomitant with other cardiac diseases. Aconitine was used to induce arrhythmia in vivo. To understand its electrophysiological fundamental, whole-cell patch-clamp was used to record the L-type calcium current (I Ca,L) and potassium currents (I K and I K1) in the ventricular myocytes in rats. Oral administration of PDQ exerted obvious antiarrhythmic effects, as indicated by the decreased incidence rate, lower number of occurrences, and shorter duration time of ventricular tachycardia and ventricular tachycardia, decreased mortality rate and increased survival time. I Ca,L and I K were inhibited by PDQ treatment while I K1 was not affected. To conclude, PDQ may have an anti-arrhythmia effect through inhibiting I Ca,L and I K. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35518596 PMCID: PMC9055354 DOI: 10.1039/d0ra01683g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
The mortality rate, VT incidence and VF incidencea
| Group | Mortality rate (%) | VT incidence (%) | VF incidence (%) |
|---|---|---|---|
| Normal | 0.0 | 0.0 | 0.0 |
| PEG 4000 | 40.0 | 100.0 | 60.0 |
| Model | 40.0# | 100.0## | 60.0## |
| L-PDQ | 20.0 | 100.0 | 30.0 |
| M-PDQ | 10.0 | 100.0 | 10.0* |
| H-PDQ | 0.0** | 90.0 | 0.0** |
| Positive | 0.0** | 30.0** | 20.0 |
Compared with normal group, #p < 0.05, ##p < 0.01; compared with model group, **p < 0.01.
Fig. 1Effects of PDQ on survival time of aconitine-induced arrhythmias (compared with normal group, #p < 0.05; compared with model group, **p < 0.01).
Fig. 2Effects of PDQ on duration time (A) and number of occurrences (B) of ventricular tachycardia (VT) (compared with model group, *p < 0.05, **p < 0.01).
Effects of PDQ on action potential in rat ventricular myocytes in vitro (±s)a
| Group | Dose (μg mL−1) | APA (mV) |
| RP (mV) | APD50 (ms) | APD90 (ms) |
|---|---|---|---|---|---|---|
| Normal | — | 107.96 ± 5.73 | 13.49 ± 1.40 | −82.85 ± 4.32 | 253.65 ± 42.23 | 296.52 ± 39.23 |
| PDQ-1 | 0.002 | 107.11 ± 5.71 | 13.87 ± 1.79 | −82.44 ± 5.95 | 251.80 ± 49.93 | 296.58 ± 44.97 |
| PDQ-2 | 0.02 | 108.45 ± 5.13 | 12.21 ± 0.90 | −82.06 ± 7.78 | 265.15 ± 49.52 | 310.88 ± 41.68 |
| PDQ-3 | 0.2 | 106.37 ± 2.02 | 12.97 ± 1.56 | −82.53 ± 2.63 | 277.57 ± 48.83 | 327.35 ± 39.41 |
| PDQ-4 | 2.0 | 104.39 ± 10.96 | 13.87 ± 2.75 | −74.07 ± 3.46** | 291.77 ± 47.20 | 346.32 ± 37.29* |
| PDQ-5 | 20.0 | 91.10 ± 2.48*** | 12.36 ± 2.61 | −69.75 ± 4.78*** | 315.00 ± 53.56 | 364.40 ± 40.74** |
Compared with normal group, *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 3Effects of PDQ on current–voltage curve of ICa,L in different groups.
Fig. 4Effects of PDQ on current–voltage curve of IK.
Fig. 5Effects of PDQ on current–voltage curve of IK1.
Fig. 6Docked poses of PDQ in 4TMF (A) and 2A79 (B).